Copyright
©The Author(s) 2021.
World J Hepatol. Dec 27, 2021; 13(12): 1919-1935
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.1919
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.1919
Table 4 Sensitivity and specificity of non-invasive biomarkers in liver fibrosis
Marker | Parameters involved | Disease | AUROC for liver fibrosis | Sensitivity | Specificity | Ref. |
AST/ALT ratio | AST and ALT | NAFLD; HCV | 0.83; - | 74; 47 | 78; 96 | McPherson et al[87]; Park et al[88] |
BARD score | BMI, AST, ALT, DM | NAFLD | 0.76 | 74 | 66 | Sun et al[89] |
APRI | AST, platelet count | NAFLD | 0.67 | 27 | 89 | McPherson et al[87] |
ALT | ALT | HCV | 0.716-0.815 | - | - | Pradat et al[59] |
Forns index | Age, platelet count, GGT, cholesterol | HCV | 0.81-0.86 | 94 | 51 | Forns et al[60] |
PGA and PGAA | Prothrombin time, GGT, apolipoprotein A1, α2 macroglobulin | Acute liver disease | 0.84-0.86 | - | - | Nguyen-Khac et al[90] |
FIB-4 | Platelet count, AST, ALT, age | HCV; NAFLD | 0.74-0.77; 0.85 | 67; 84 | 71; 69 | Sebastiani[23]; Sun et al[89] |
Fibro test | Haptoglobin, apolipoprotein A1, α2 macroglobulin, GGT, bilirubin, age, and gender | HBV; HCV; ALD | 0.84; 0.87; 0.83 | 61; 75; - | 80; 85; - | Salkic et al[91]; Imbert-Bismut et al[66]; Naveau et al[62] |
Hepascore | GGT, bilirubin, HA, α2 macroglobulin, age, and gender | HCV | 0.82 | - | - | Naveau et al[62], Adams et al[92] |
SHASTA index | HA, AST, and albumin | HCV | 0.87 | 50 | 94 | Kelleher et al[93] |
Fibrospect II | α2 macroglobulin, HA, and TIMP-1 | HCV | 0.82-0.83 | 77-83 | 66-73 | Patel et al[94] |
- Citation: Kaur N, Goyal G, Garg R, Tapasvi C, Chawla S, Kaur R. Potential role of noninvasive biomarkers during liver fibrosis. World J Hepatol 2021; 13(12): 1919-1935
- URL: https://www.wjgnet.com/1948-5182/full/v13/i12/1919.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i12.1919